FilingReader Intelligence
Zhongsheng Pharma subsidiary secures European patent for antiviral drug
July 17, 2025 at 10:50 AM UTC•By FilingReader AI
Guangdong Zhongsheng Pharmaceutical announced its subsidiary Guangdong Zhongsheng Ruichuang Biotechnology received a European patent for an anti-influenza virus compound.
The patent covers Anglabivir, an innovative drug approved in May 2025 for treating adult patients with simple type A influenza. The compound patents have already been granted in numerous countries including China, the United States, Japan, South Korea, Australia, Canada, Brazil, and others.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:002317•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Guangdong Zhongsheng Pharmaceutical publishes news
Free account required • Unsubscribe anytime